

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4976624

| | |
|---|--------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| ESTELLE TRIFILIEFF | 03/18/2016 |
| JEROME FEIGE | 03/24/2016 |
| RONENN ROUBENOFF | 03/15/2016 |
| SHINJI HATAKEYAMA | 03/16/2016 |
| RECEIVING PARTY DATA | |
| Name: | NOVARTIS PHARMA AG |
| Street Address: | ST. JOHANN, POSTFACH |
| Internal Address: | FORUM 1, NOVARTIS CAMPUS |
| City: | BASEL |
| State/Country: | SWITZERLAND |
| Postal Code: | 4056 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 15774327 |
| CORRESPONDENCE DATA | |
| Fax Number: | (973)781-8064 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 862-778-3423 |
| Email: | pip_inbox.phchbs@novartis.com |
| Correspondent Name: | NOVARTIS PHARMACEUTICALS CORPORATION |
| Address Line 1: | 1 HEALTH PLAZA |
| Address Line 4: | EAST HANOVER, NEW JERSEY 07936 |
| ATTORNEY DOCKET NUMBER: | PAT057144-US-PCT |
| NAME OF SUBMITTER: | LAUREN BOSCO |
| SIGNATURE: | /Lauren Bosco/ |
| DATE SIGNED: | 05/24/2018 |
| Total Attachments: 20 | |
| source=PAT057144-US-PSP Assignment from Invts to NPAG#page1.tif | |

source=PAT057144-US-PSP Assignment from Invts to NPAG#page2.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page3.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page4.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page5.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page6.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page7.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page8.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page9.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page10.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page11.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page12.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page13.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page14.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page15.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page16.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page17.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page18.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page19.tif
source=PAT057144-US-PSP Assignment from Invts to NPAG#page20.tif

ASSIGNMENT

This Assignment Agreement is entered into by and between **ESTELLE TRIFILIEFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **FRANCE**; **JEROME FEIGE**, **RUE DES ALPES 21**, **CH-1023**, **CRISSIER**, **SWITZERLAND**, a citizen of **FRANCE**; **RONENN ROUBENOFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **4002 BASEL**, **SWITZERLAND**, a citizen of **UNITED STATES OF AMERICA**; **SHINJI HATAKEYAMA**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **JAPAN** (hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, **ST. JOHANN**, **POSTFACH**, **FORUM 1**, **NOVARTIS CAMPUS**, **4056 BASEL**, **SWITZERLAND**, a company organized under the laws of **SWITZERLAND**.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG**, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF

and filed in the United States Patent and Trademark Office on **11 November, 2015** and accorded Application Number **62/253,896** and/or filed as a PCT International Application on _____ and accorded International Patent Application Number PCT/ _____;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 18 day of March 2016.


ESTELLE TRIFILIEFF

LUCRICH HASSLER Coltzy Seepers
Witness

JÜRGE GASSER J. Gasser
Witness

Executed this _____ day of _____ 2016.

SHINJI HATAKEYAMA

Witness

Witness

Executed this _____ day of _____ 2016.

RONENN ROUBENOFF

Witness

Witness

Executed this _____ day of _____ 2016.

JEROME FEIGE

Witness

Witness

NOVARTIS PHARMA AG

Executed this 8th day of April 2016.

BY: Cindy Klepacky
NAME: Cindy Klepacky, Authorized Signatory
Authorized Signatory

BY: Kelly Stritenberger
NAME: Kelly Stritenberger, authorized signatory
Authorized Signatory

Witness: Lore Douglas

Witness: Mark Lorenson

ASSIGNMENT

This Assignment Agreement is entered into by and between **ESTELLE TRIFILIEFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **FRANCE**; **JEROME FEIGE**, **RUE DES ALPES 21**, **CH-1023**, **CRISSIER**, **SWITZERLAND**, a citizen of **FRANCE**; **RONENN ROUBENOFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **4002 BASEL**, **SWITZERLAND**, a citizen of **UNITED STATES OF AMERICA**; **SHINJI HATAKEYAMA**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **JAPAN** (hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, **ST. JOHANN**, **POSTFACH**, **FORUM 1**, **NOVARTIS CAMPUS**, **4056 BASEL**, **SWITZERLAND**, a company organized under the laws of **SWITZERLAND**.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG**, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF

and filed in the United States Patent and Trademark Office on **11 November, 2015** and accorded Application Number **62/253,896** and/or filed as a PCT International Application on _____ and accorded International Patent Application Number PCT/ _____;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____ 2016.

ESTELLE TRIFILIEFF

Witness

Witness

Executed this _____ day of _____ 2016.

SHINJI HATAKEYAMA

Witness

Witness


Executed this _____ day of _____ 2016.

RONENN ROUBENOFF

Witness

Witness

Executed this 24 day of March 2016.



JEROME FEIGE

Clara Becker C. 25

Witness

Alice Pambou [Signature]

Witness

NOVARTIS PHARMA AG

Executed this 8th day of April 2016.

BY: Cindy Klepacky
NAME: Cindy Klepacky, Authorized Signatory
Authorized Signatory

BY: Kelly Stritenberger
NAME: Kelly Stritenberger, authorized signatory
Authorized Signatory

Witness: John Douglas

Witness: Mark Brown

ASSIGNMENT

This Assignment Agreement is entered into by and between **ESTELLE TRIFILIEFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **FRANCE**; **JEROME FEIGE**, **RUE DES ALPES 21**, **CH-1023**, **CRISSIER**, **SWITZERLAND**, a citizen of **FRANCE**; **RONENN ROUBENOFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **4002 BASEL**, **SWITZERLAND**, a citizen of **UNITED STATES OF AMERICA**; **SHINJI HATAKEYAMA**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **JAPAN** (hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, **ST. JOHANN**, **POSTFACH**, **FORUM 1**, **NOVARTIS CAMPUS**, **4056 BASEL**, **SWITZERLAND**, a company organized under the laws of **SWITZERLAND**.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG**, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF

and filed in the United States Patent and Trademark Office on **11 November, 2015** and accorded Application Number **62/253,896** and/or filed as a PCT International Application on _____ and accorded International Patent Application Number PCT/_____;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____ 2016.

ESTELLE TRIFILIEFF

Witness

Witness

Executed this _____ day of _____ 2016.

SHINJI HATAKEYAMA


Witness

Witness


Executed this _____ day of _____ 2016.



RONENN ROUBENOFF



Witness



Witness

Executed this 15th day of March 2016.

JEROME FEIGE

Witness

Witness

NOVARTIS PHARMA AG

Executed this 8th day of April 2016.

BY: Cindy Kiepach

NAME: Cindy Kiepach, Authorized Signatory

Authorized Signatory

BY: Kelly Strienberger

NAME: Kelly Strienberger, authorized signatory

Authorized Signatory

Witness: JOSE DOUGLAS

Witness: Mark Lazarov

ASSIGNMENT

This Assignment Agreement is entered into by and between **ESTELLE TRIFILIEFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **FRANCE**; **JEROME FEIGE**, **RUE DES ALPES 21**, **CH-1023**, **CRISSIER**, **SWITZERLAND**, a citizen of **FRANCE**; **RONENN ROUBENOFF**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **4002 BASEL**, **SWITZERLAND**, a citizen of **UNITED STATES OF AMERICA**; **SHINJI HATAKEYAMA**, c/o **NOVARTIS PHARMA AG**, **FABRIKSTRASSE**, **POSTFACH**, **4002 BASEL**, **SWITZERLAND**, a citizen of **JAPAN** (hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, **ST. JOHANN**, **POSTFACH**, **FORUM 1**, **NOVARTIS CAMPUS**, **4056 BASEL**, **SWITZERLAND**, a company organized under the laws of **SWITZERLAND**.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG**, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF

and filed in the United States Patent and Trademark Office on **11 November, 2015** and accorded Application Number **62/253,896** and/or filed as a PCT International Application on _____ and accorded International Patent Application Number PCT/ _____;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____ 2016.

ESTELLE TRIFILIEFF

Witness

Witness

Executed this 16 day of March 2016.


SHINJI HATAKEYAMA


Witness


Witness

Executed this _____ day of _____ 2016.

RONENN ROUBENOFF

Witness

Witness

Executed this _____ day of _____ 2016.

JEROME FEIGE

Witness

Witness

NOVARTIS PHARMA AG

Executed this 9th day of April 2016.

BY: Cindy Klepacky

NAME: Cindy Klepacky, Authorized Signatory
Authorized Signatory

BY: Kelly Stritenberger

NAME: Kelly Stritenberger, authorized signatory
Authorized Signatory

Witness: JOSE DOUGLAS

Witness: Mark Lazoren